Search - tctmd.com

Displaying 41 - 60 of 87

Sort: Relevancy | Date

Bioprosthetic structural valve degeneration

Presentation CDM 2018

TAVR is Here to Stay: What About TAVR in Low-Risk Patients?

Presenter: Joseph P. Carrozza

October 12, 2018

Presentation TCT 2018

The Case for TAVR in Low-Risk Patients: Rationale, Current Data, Clinical Trends, and Updates from the Ongoing Clinical Trials

Presenter: Allan Schwartz, Stephan Windecker, Jeffrey J. Popma

September 22, 2018

Presentation The Structural Heart Disease Summit 2018

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

Presenter: Susheel K. Kodali, Michael J. Reardon, Patrick M. McCarthy

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

Presenter: Lars Sondergaard

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

UK All-Comers

Presenter: Neil E. Moat

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Evolut R Low-Risk

Presenter: Jeffrey J. Popma

June 21, 2018

Presentation The Structural Heart Disease Summit 2018

Partner 3 Low-Risk

Presenter: Martin B. Leon

June 21, 2018

Presentation CRT 2018

Transcatheter Aortic Valve Replacement for Patients with Severe Aortic Stenosis who are at Low Risk For Mortality: Interim results from the Prospective Multicenter LRT Clinical Trial

Presenter: Ron Waksman

March 04, 2018

Presentation

Efficacy of High-Sensitivity Troponin T in Identifying Very-Low-Risk Patients With Possible ACS

December 14, 2017

Presentation TCT 2017

The NOTION 2 Low-risk Trial in Younger Patients

Presenter: Lars Sondergaard

October 30, 2017

Presentation TCT 2017

Germany Presents: Future Perspective - TAVR Compared to Surgical Valve Replacement in Patients With Low-Risk Scores Potential Benefits and Harms

Presenter: Dariusz Dudek, Martin Hudec, Michael Haude

October 30, 2017

Presentation TCT 2017

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

Presenter: David H. Adams, Ted Feldman, Craig R. Smith

October 30, 2017

Presentation TCT 2017

TAVR in Low-Risk Patients

Presenter: Jeroen J. Bax, Axel Linke, Thomas Pilgrim

October 29, 2017

Presentation TVT 2017

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

Presenter: David J. Cohen, Jeffrey J. Popma

June 16, 2017

Presentation SIF 2017

TAVR Will Be Default in Low Risk Patients

Presenter: David L. Brown

March 11, 2017

Presentation TCT 2016

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Presenter: Nicole Ibrahim, Martin B. Leon, Jaime Raben

November 01, 2016

Presentation TCT 2016

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Presenter: Andreas Baumbach, David Hildick-Smith, Wilson Y. Szeto

November 01, 2016

Presentation TCT 2016

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Presenter: Raj Makkar, Lars Sondergaard, Stephen J.D. Brecker

October 31, 2016

Presentation TCT 2016

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

Presenter: Raj Makkar, Lars Sondergaard, Antonio Colombo

October 31, 2016

Presentation TCT 2016

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Presenter: Niall T. Mulvihill, Michael Mahmoudi

October 31, 2016

Advertisement

TAVR is Here to Stay: What About TAVR in Low-Risk Patients?

The Case for TAVR in Low-Risk Patients: Rationale, Current Data, Clinical Trends, and Updates from the Ongoing Clinical Trials

Counterpoint: Most Bicuspid Aortic Valves (Especially In Younger Low-Risk Patients) Will Remain in the Surgical Domain!

NOTION 1 - Five-Year FU and Notion 2 - Young & Low-Risk

UK All-Comers

Evolut R Low-Risk

Partner 3 Low-Risk

Transcatheter Aortic Valve Replacement for Patients with Severe Aortic Stenosis who are at Low Risk For Mortality: Interim results from the Prospective Multicenter LRT Clinical Trial

Efficacy of High-Sensitivity Troponin T in Identifying Very-Low-Risk Patients With Possible ACS

The NOTION 2 Low-risk Trial in Younger Patients

Germany Presents: Future Perspective - TAVR Compared to Surgical Valve Replacement in Patients With Low-Risk Scores Potential Benefits and Harms

Predicting the Future: Will the Ongoing LOW RISK TAVR Trials Change How We Treat Low Surgical Risk Patients With Aortic Stenosis?

TAVR in Low-Risk Patients

SURTAVI Vignette II: Subset Analysis of Patients With STS < 3% (Lower-Risk Patients)

TAVR Will Be Default in Low Risk Patients

FDA Perspectives on TAVR Label Expansion (E.G. Lower Risk Patients, Bicuspid Aortic Stenosis and Aortic Insufficiency), and New and Iterative Device Approval Pathways

Debate - Should TAVR Be Offered to Every Patient With Aortic Stenosis? No, Given All the Uncertainties About Durability, Valve Thrombus, etc. - Wait for the Data in Low-risk Patients!

Flash Debate: Counterpoint In Lower Risk Patients, A Thoughtful Hybrid Strategy Is Preferred!

Flash Debate: Point In Lower Risk Patients, the Minimalist Strategy Should Be the Default Approach!

TAVR for Intermediate-Risk and Low-Risk Patients: Review of the Literature

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content